22 April 2015Americas

Kyle Bass launches IPR challenge against Imbruvica patent

Texas hedge fund manager Kyle Bass has sought another inter partes review (IPR), this time to challenge a patent covering Pharmacyclics’ cancer drug Imbruvica (ibrutinib).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk